Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Latest Biotechnology and ACADIA Pharmaceuticals Inc., Xenon Pharmaceuticals Inc. Stock News

As of March 6, 2026, ACADIA Pharmaceuticals Inc. had a $3.8 billion market capitalization, compared to the Biotechnology median of $273.7 million. ACADIA Pharmaceuticals Inc.’s stock is down 18.5% in 2026, down 4.6% in the previous five trading days and up 22.57% in the past year.

Currently, ACADIA Pharmaceuticals Inc.’s price-earnings ratio is 9.6. ACADIA Pharmaceuticals Inc.’s trailing 12-month revenue is $1.1 billion with a 36.5% net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $0.497 per share for the current fiscal year. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

As of March 6, 2026, Xenon Pharmaceuticals Inc. had a $3.5 billion market cap, putting it in the 62nd percentile of all stocks. Xenon Pharmaceuticals Inc.’s stock is up 33.4% in 2026, up 40.5% in the previous five trading days and up 12.83% in the past year.

Currently, Xenon Pharmaceuticals Inc. does not have a price-earnings ratio. Xenon Pharmaceuticals Inc.’s trailing 12-month revenue is $7.5 million with a % net profit margin. As of March 6, 2026, Xenon Pharmaceuticals Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.850 per share for the current fiscal year. Xenon Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. Stock Value Grades

Company	Ticker	Value
ACADIA Pharmaceuticals Inc.	ACAD	D
Xenon Pharmaceuticals Inc.	XENE	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

ACADIA Pharmaceuticals Inc. has a Value Score of 30, which is Expensive. Xenon Pharmaceuticals Inc. has a Value Score of 7, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. is the better investment when it comes to value.

ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.’s Quality Grades

Company	Ticker	Quality
ACADIA Pharmaceuticals Inc.	ACAD	B
Xenon Pharmaceuticals Inc.	XENE	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

ACADIA Pharmaceuticals Inc. has a Quality Score of 78, which is Strong. Xenon Pharmaceuticals Inc. has a Quality Score of 30, which is Weak.

The Quality Grade Winner: ACADIA Pharmaceuticals Inc.

As you can clearly see from the Quality Grade breakdown above, ACADIA Pharmaceuticals Inc. has a better overall quality grade than Xenon Pharmaceuticals Inc.. For investors who are looking for companies with higher quality than others in the same industry, ACADIA Pharmaceuticals Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.’s Momentum Grades

Company	Ticker	Momentum
ACADIA Pharmaceuticals Inc.	ACAD	C
Xenon Pharmaceuticals Inc.	XENE	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ACADIA Pharmaceuticals Inc. has a Momentum Score of 46, which is Average. Xenon Pharmaceuticals Inc. has a Momentum Score of 47, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. is the better investment when it comes to momentum.

Other ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. Grades

In addition to Value, Momentum and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. Stock?

Overall, ACADIA Pharmaceuticals Inc. stock has a Value Score of 30, Momentum Score of 46 and Quality Score of 78.

Xenon Pharmaceuticals Inc. stock has a Value Score of 7, Momentum Score of 47 and Quality Score of 30.

Comparing ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.